pembrolizumab
Pembrolizumab, sold under the brand name Keytruda, is a humanized monoclonal antibody, more specifically a PD-1 inhibitor, used in cancer immunotherapy to treat many types of cancer. It is administered by slow intravenous injection.
Key facts
- Drug.type
- mab
- Drug.image
- Pembrolizumab 5DK3.png
- Drug.caption
- From PDB entry
- Drug.mab_type
- mab
- Drug.source
- zu/o
- Drug.target
- PD-1
- Drug.tradename
- Keytruda
- Drug.MedlinePlus
- a614048
- Drug.DailyMedID
- Pembrolizumab
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- Intravenous
- Drug.class
- Antineoplastic
- Drug.ATC_prefix
- L01
Article
12 sectionsContents
- Medical uses
- Adverse effects
- Mechanism of action
- Pharmacology
- Chemistry and manufacturing
- History
- Society and culture
- Economics
- Research
- References
- Further reading
- External links
Pembrolizumab, sold under the brand name Keytruda, is a humanized monoclonal antibody, more specifically a PD-1 inhibitor, used in cancer immunotherapy to treat many types of cancer. It is administered by slow intravenous injection.
Common side effects include fatigue, musculoskeletal pain, decreased appetite, itchy skin, diarrhea, nausea, rash, fever, cough, difficulty breathing, constipation, pain, and abdominal pain. It is an IgG4 isotype antibody that blocks a protective mechanism of cancer cells, allowing the immune system to destroy them. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes.
Gallery (2)
Connections
Categories
Antineoplastic drugsCancer immunotherapyChemicals that do not have a ChemSpider ID assignedDrugs developed by Merck & Co.Drugs that are a monoclonal antibodyDrugs with non-standard legal statusECHA InfoCard ID from WikidataMonoclonal antibodies for tumorsOrphan drugsSource attributionTissue agnostic antineoplastic agentsWorld Health Organization essential medicines